Pepholin, a bacteriophage holin-derived peptide, eradicates MDR P. aeruginosa in burn wounds
Background
Multidrug-resistant (MDR) Pseudomonas aeruginosa poses a critical threat to burn wound healing, as conventional antibiotics are increasingly ineffective. This necessitates novel therapeutic strategies to combat these persistent infections. Antimicrobial peptides (AMPs) offer a promising alternative, but new scaffolds are needed. Bacteriophage holins, proteins that disrupt bacterial membranes, represent an underexplored source for designing potent AMPs. This study investigates a holin-derived peptide to address the urgent need for effective anti-MDR agents.
Study Design
Researchers used an AI-guided strategy to design Pepholin, a 12-amino acid antimicrobial peptide derived from a Pseudomonas bacteriophage holin. In vitro, they assessed its antibacterial and antibiofilm activities against MDR P. aeruginosa, membrane disruption via permeabilization assays, hemocompatibility, and mammalian cell cytotoxicity. For in vivo evaluation, Pepholin was formulated into a carbomer-based hydrogel and applied topically to a murine burn wound infection model challenged with MDR P. aeruginosa. Primary endpoints included bacterial clearance, wound healing rates, collagen deposition, and modulation of cytokine responses.
Results
Mechanistic studies confirmed its bactericidal action by permeabilizing and disrupting bacterial membranes in a concentration and time-dependent manner. The peptide exhibited high hemocompatibility and minimal cytotoxicity in mammalian cells, with selectivity indices greater than 8. Crucially, Pepholin maintained its antibacterial efficacy under physiological conditions, including high salt, serum, and body temperature. In the murine burn wound infection model, topical treatment with the Pepholin hydrogel significantly enhanced bacterial clearance from the wounds. Furthermore, it accelerated the overall wound healing process, promoted robust collagen deposition, and favorably modulated local cytokine responses, indicating a comprehensive therapeutic effect beyond just bacterial killing.
Key Findings
- Pepholin eradicated MDR P. aeruginosa completely within 90 minutes in vitro.
- Pepholin exhibited high hemocompatibility and minimal cytotoxicity, with selectivity indices > 8.
- Topical Pepholin hydrogel significantly enhanced bacterial clearance in murine burn wounds.
- Pepholin accelerated wound healing and promoted collagen deposition in infected burn wounds.
- The peptide retained antibacterial activity under physiological salt, serum, and temperature conditions.
Why It Matters
Pepholin represents a significant step towards combating life-threatening MDR P. aeruginosa burn wound infections, offering a novel mechanism of action distinct from conventional antibiotics. For clinicians, this opens the door to a new class of antimicrobial agents, particularly for difficult-to-treat topical infections where resistance is rampant. The successful hydrogel formulation suggests a practical delivery method for future clinical use, potentially reducing systemic side effects. While still preclinical, the strong efficacy, biocompatibility, and stability of Pepholin position it as a leading candidate for next-generation therapeutics, potentially altering future wound care protocols by providing an effective alternative where current treatments fail.
pepholin
antimicrobial-peptide
mdr-p-aeruginosa
burn-wounds
wound-healing
bacteriophage